



Pharmaids Pharmaceuticals Limited

Date: 28.05.2024

To
The Manager
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai – 400001

Dear Sir/Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Submission of Audited Standalone and Consolidated Financial Results along with Auditors' Report for the quarter and year ended 31st March, 2024

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Audited Standalone and Consolidated Financial Results along with Auditors' Report with unmodified opinion for the quarter and Financial Year ended 31st March, 2024.

The Financial Results are also available on the website of the Company at www.pharmaids.com and on the website of BSE www.bseindia.com

The Board Meeting commenced at 04:50 P.M. and concluded at 06:20 P.M.

This is for your information and Records.

Thanking You,

Yours' Faithfully

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar
(Company Secretary & Head-Legal)

INDEPENDENT AUDITOR'S REPORT

To,
The Board of Directors,
Pharmaids Pharmaceuticals Limited

REPORT ON THE AUDIT OF THE STANDALONE FINANCIAL RESULTS

Opinion

We have audited the accompanying standalone quarterly financial results of Pharmaids Pharmaceuticals Limited (the company) for the quarter ended 31st March 2024 and the year to date results for the period from 1st April 2023 to 31st March 2024, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the quarter ended 31st March 2024 as well as the year to date results for the period from 1st April 2023 to 31st March 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting

Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to

continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone financial results include the results for the quarter ended 31 March 2024 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.


For PPKG & Co
Chartered Accountants

(Firm's Registration No. 009655S)


Giridhari Lal Toshniwal
(Partner)

(Membership No. 205140)

UDIN: 24205140BKALIX6873



Place: Hyderabad

Date: 28th May 2024

PHARMAIDS PHARMACEUTICALS LIMITED

Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Statement of Standalone Audited Financial Results for the Quarter and Twelve Months ended 31st March, 2024

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
	Mar 31, 2024	Dec 2023	Mar 31, 2023	Mar 31, 2024	Mar 31, 2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Income					
Revenue from operations	0.70	2.08	-	2.78	-
Other income	3.07	76.14	-	79.50	-
Total income	3.77	78.22	-	82.27	-
Expenses					
Cost of materials consumed	-	-	-	-	-
Purchase of stock-in-trade	23.55	1.87	-	25.42	-
Changes in inventories of finished goods and work-in-progress	(22.93)	-	88.76	(22.93)	88.76
Employee benefits expense	78.95	48.99	42.28	198.78	113.10
Finance costs	28.67	1.56	0.18	33.34	-
Depreciation and amortisation expense	4.55	3.87	0.13	17.72	1.68
Other expenses	101.87	194.81	729.14	438.62	787.22
Total expenses	214.67	251.09	860.49	690.95	990.76
Profit/ (Loss) before exceptional items and tax	(210.89)	(172.87)	(860.49)	(608.67)	(990.76)
Exceptional items					
Prior period share of profit/interest form Associate					
Profit/ (Loss) before tax	(210.89)	(172.87)	(860.49)	(608.67)	(990.76)
Tax expense					
Current tax	-	-	-	-	-
Deferred tax	12.81	(57.57)	(244.34)	(113.69)	(235.20)
Total Tax Expense	12.81	(57.57)	(244.34)	(113.69)	(235.20)
Profit/ (Loss) for the year	(223.71)	(115.31)	(616.15)	(494.98)	(755.57)
Other comprehensive income					
(i) Items that will not be reclassified subsequently to profit or loss					
Re-measurement on defined benefit plans and equity instruments	-	-	-	-	-
Income tax effect	-	-	-	-	-
(ii) Items that will be reclassified subsequently to profit or loss					
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-	-
Income tax effect	-	-	-	-	-

PHARMAIDS PHARMACEUTICALS LIMITED

Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Statement of Standalone Audited Financial Results for the Quarter and Twelve Months ended 31st March, 2024

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
	Mar 31, 2024	Dec 2023	Mar 31, 2023	Mar 31, 2024	Mar 31, 2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Other comprehensive income for the year, net of taxes	-	-	-	-	-
Total comprehensive income for the year	(223.71)	(115.31)	(616.15)	(494.98)	(755.57)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	2,144.38	2,144.38	3,526.78	2,144.38
Other Equity (excluding revaluation reserve)				3,579.31	63.46
Earnings per equity share					
Basic (in Rs)	(0.98)	(0.54)	(4.79)	(2.18)	(5.86)
Diluted (in Rs)	(0.98)	(0.54)	(4.79)	(2.18)	(5.86)

By the order of the Board of Directors
For Pharmajids Pharmaceuticals Limited

Venu Madhava Kaparthy
Director
DIN: 00021699

Notes to Accounts:

1. The Audited Interim condensed Standalone Financial Results of the Company for the Quarter and Year ended March 31, 2024 have been audited by the Statutory Auditors of the Company. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective Meetings held on May 28, 2024.
2. The Financial Results have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter, for the year ended March 31, 2024 have been audited by the Statutory Auditors of the Company.
3. The Statement includes the result for the Quarter ended March 31, 2024 being the balancing figure between Audited Figures in respect of the full Financial Year ended March 31, 2024 and the Figures for the nine months period ended December 31, 2023, which was subjected to Limited Review.
4. Figures for the previous periods have been regrouped / reclassified wherever considered necessary.

By the order of the Board of Directors
For Pharmajids Pharmaceuticals Limited

Venu Madhava Kaparthy
Director
DIN: 00021699

Standalone Balance Sheet

All figures in Rs. Lacs unless otherwise specified

Particulars	As at	As at
	31 March 2024	31 March 2023
	(Audited)	(Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,613.85	10.61
Capital work-in-progress	229.72	200.00
Right-of-use assets	41.32	-
Financial assets		
(i) Investments	5,259.54	-
(ii) Other financial assets	495.17	8.50
Deferred tax assets (net)	384.44	270.75
Other non-current assets	-	137.06
Total non-current assets	8,024.05	626.92
Current assets		
Inventories	22.93	-
Financial assets		
(i) Investments	-	327.04
(ii) Trade receivables	-	205.43
(iii) Cash and cash equivalents	245.93	1,275.42
Other current assets	207.16	20.19
Total current assets	476.01	1,828.07
TOTAL ASSETS	8,500.06	2,454.99
EQUITY AND LIABILITIES		
Equity		
Equity share capital	3,526.78	2,144.38
Other equity	3,579.31	98.15
Total equity	7,106.09	2,242.53
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	1,250.00	-
(ii) Lease liabilities	27.79	-
Provisions	5.81	-
Total non-current liabilities	1,283.60	-
Current liabilities		
Financial liabilities		
(i) Lease liabilities	14.71	-
(ii) Trade payables		
total outstanding dues of micro and small enterprises	-	-
total outstanding dues of creditors other than micro and small enterprises	-	188.31
(iii) Other financial liabilities	76.64	16.67
Provisions	0.48	-
Other current liabilities	18.55	7.49
Total Current Liabilities	110.37	212.47
TOTAL EQUITY AND LIABILITIES	8,500.06	2,454.99

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Director
DIN: 00021699

Standalone Statement of Cash Flows

All figures in Rs. Lacs unless otherwise specified

Particulars	Year ended	Year ended
	31 March 2024	31 March 2023
	(Audited)	(Audited)
Cash flows from operating activities		
Net Profit Before Tax	(608.67)	(990.76)
<i>Adjustments to reconcile profit before tax to net cash flows:</i>		
Depreciation	17.72	1.68
Interest income	(14.83)	-
Finance Cost	33.34	-
Liabilities written back	(64.61)	-
(Gain)/ Loss on sale of fixed asset	-	3.06
Provision for bad debts	80.81	-
Share of loss in partnership firm	206.53	-
<i>Adjustments for changes in working capital:</i>		
(Increase)/decrease in inventories	(22.93)	88.76
(Increase)/decrease in trade receivables	205.43	70.06
(Increase)/decrease in other current assets	(49.91)	456.87
Increase/(decrease) in trade payables	(188.31)	(42.27)
Increase/(decrease) in other financial liabilities	59.97	16.67
Increase/(decrease) in other provisions	6.29	-
Increase/(decrease) in other current liabilities	(5.14)	(6.00)
Cash generated from/(used in) operations	(344.32)	(401.93)
Income tax paid	-	-
Net cash flows generated from/(used in) operating activities (A)	(344.32)	(401.93)
Cash flows from investing activities		
Purchase of property, plant and equipment incl. CWIP	(1,637.28)	(167.29)
Interest on bank deposits	12.84	-
Investment in subsidiaries	(5,626.48)	(327.04)
Net cash flow generated from/(used in) investing activities (B)	(7,250.92)	(494.33)
Cash flow from Financing activities		
Repayment of borrowing	(125.00)	-
Proceeds from borrowing	1,375.00	-
Proceeds from issue of equity shares	5,358.55	2,096.25
Proceeds from share application money	-	34.69
Interest on loan	(27.11)	-
Repayment of lease liabilities	(15.69)	-
Net cash flow generated from/(used in) financing activities (C)	6,565.75	2,130.94
Net increase in cash and cash equivalents (A+B+C)	(1,029.49)	1,234.67
Cash and cash equivalents at the beginning of the year	1,275.42	40.74
Cash and cash equivalents at the end of the year	245.93	1,275.42
Cash and cash equivalents comprise		
Cash on hand	0.46	0.31
Balances with banks in current & deposit accounts	45.51	1,275.10
Deposits with original maturity of less than 3 months	199.96	-
Total cash and cash equivalents	245.93	1,275.42

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Director
DIN: 00021699

INDEPENDENT AUDITOR'S REPORT

To,
The Board of Directors,
Pharmaids Pharmaceuticals Limited (Holding Company)

REPORT ON THE AUDIT OF CONSOLIDATED FINANCIAL RESULTS

Opinion

We have audited the accompanying consolidated annual financial results of **Pharmaids Pharmaceuticals Limited** (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the year ended 31st March 2024, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('LODR Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements /financial results/ financial information of the subsidiaries, the aforesaid consolidated financial results:

- i. include the annual financial results of the entities mentioned in *Annexure I* to the aforesaid consolidated annual financial results.
- ii. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- iii. give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the Group for the year ended 31st March 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation

and presentation of these consolidated financial results that give a true and fair view of the net loss and other comprehensive income and other financial information of the Group including its associates in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, as amended, to the extent applicable.

Other Matters


We did not audit the annual financial statements/ financial information of 2 subsidiaries included in the Statement, whose financial information (prior to consolidation adjustments) reflects total assets of 45.69 crores as at 31 March 2024, total revenues of 15.67 crores, total net loss after tax of 8.92 crores, total comprehensive income of (9.24 crores), and net cash outflows of 1.53 crores for the year ended on that date, as considered in the Statement. The Statement also includes the Group's share of net loss (including other comprehensive income) of 8.08 crores for the year ended 31 March 2024, in respect of 2 Subsidiaries, whose annual financial statements have not been audited by us. This annual financial statements / financial information have been audited by other auditors whose audit reports have been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and is based solely on the audit reports of such other auditors, and the procedures performed by us as stated in paragraph 8 above.

Our opinion, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based on the audit report of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by us. Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.

This statement includes the consolidated Financial Results for the quarter ended 31st March 2024, being the balancing figure between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter of the current financial year which were subject to limited review by us.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)


Giridhari Lal Toshniwal
(Partner)

(Membership No. 205140)

UDIN No- 24205140BKALIY4746



Place: Hyderabad
Date: 28th May 2024

Annexure I

List of entities included in consolidated annual financial results.

SL.No.	Name of the Company	Relationship
1	Adita Bio Sys Private Limited	Subsidiary Company
2	Anugraha Chemicals	Subsidiary
3	Siri Labvivo Diet Private Limited	Step down subsidiary company
4	Spring Labs	Step down subsidiary

PHARMAIDS PHARMACEUTICALS LIMITED

Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Statement of Consolidated Audited Financial Results for the Quarter and Twelve Months ended 31st March, 2024

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
	Mar 31, 2024	Dec 2023	Mar 31, 2023	Mar 31, 2024	Mar 31, 2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Income					
Revenue from operations	580.59	2.08	-	1,511.21	-
Other income	11.92	76.14	-	87.82	-
Total income	592.51	78.22	-	1,599.03	-
Expenses					
Cost of materials consumed	277.52	-	-	1,026.66	-
Purchase of stock-in-trade	28.08	1.87	-	4.40	-
Changes in inventories of finished goods and work-in-progress	81.38	-	88.76	116.23	88.76
Employee benefits expense	393.94	48.99	42.28	919.61	113.10
Finance costs	76.65	1.56	0.18	156.83	-
Depreciation and amortisation expense	63.17	3.87	0.13	172.49	1.68
Other expenses	357.65	194.81	729.14	764.94	787.22
Total expenses	1,278.39	251.09	860.49	3,161.16	990.76
Profit/ (Loss) before exceptional items and tax	(685.88)	(172.87)	(860.49)	(1,562.14)	(990.76)
Exceptional items					
Prior period share of profit/interest from Associate					
Profit/ (Loss) before tax	(685.88)	(172.87)	(860.49)	(1,562.14)	(990.76)
Tax expense					
Current tax	-	-	-	-	-
Deferred tax	(53.22)	(57.57)	(244.34)	(377.82)	(235.20)
Total Tax Expense	(53.22)	(57.57)	(244.34)	(377.82)	(235.20)
Profit/ (Loss) for the year	(632.65)	(115.31)	(616.15)	(1,184.31)	(755.57)
Other comprehensive income					
(i) Items that will not be reclassified subsequently to profit or loss	(11.63)	-	3.48	(46.51)	3.48
Income tax effect	3.63	-	-	14.51	-
(ii) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-
Income tax effect	-	-	-	-	-
Other comprehensive income for the year, net of taxes	(8.00)	-	3.48	(32.00)	3.48
Total comprehensive income for the year	(640.65)	(115.31)	(612.67)	(1,216.31)	(752.09)

Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
	Mar 31, 2024	Dec 2023	Mar 31, 2023	Mar 31, 2024	Mar 31, 2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Profit/ (Loss) attributable to:					
Equity holders of the Holding company	(551.96)	(115.31)	(616.15)	(796.80)	(755.57)
Non-controlling interest	(80.69)	-	-	(387.51)	-
Profit/ (Loss) for the year	(632.65)	(115.31)	(616.15)	(1,184.31)	(755.57)
Other comprehensive income attributable to:					
Equity holders of the Holding company	(4.05)	-	3.48	(11.96)	3.48
Non-controlling interest	(3.95)	-	-	(20.04)	-
Other comprehensive income for the year	(8.00)	-	3.48	(32.00)	3.48
Total comprehensive income attributable to:					
Equity holders of the Holding company	(556.01)	(115.31)	(612.67)	(808.75)	(752.09)
Non-controlling interest	(84.64)	-	-	(407.55)	-
Total comprehensive income for the year	(640.65)	(115.31)	(612.67)	(1,216.31)	(752.09)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	2,144.38	2,144.38	3,526.78	2,144.38
Other Equity (excluding revaluation reserve)	-	-	-	3,579.31	63.46
Earnings per equity share					
Basic (in Rs)	(2.82)	(0.54)	(4.76)	(3.56)	(5.83)
Diluted (in Rs)	(2.82)	(0.54)	(4.76)	(3.56)	(5.83)

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**

**Venu Madhava Kaparthy
Director
DIN: 00021699**

Notes to Accounts:

1. The Consolidated Financial Results of Pharmaids(The Holding Company) and its subsidiaries (together referred to as Group) have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter, for the year ended March 31, 2024 have been audited by the Statutory Auditors of the Company.
2. The Consolidated Financial Results for the year ended 31st march 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at their respective Meetings held on May 28, 2024 and have been audited by the Statutory Auditors of the Holding Companies.
3. The Statement includes the result for the Quarter ended March 31, 2024 being the balancing figure between Audited Figures in respect of the full Financial Year ended March 31, 2024 and the Figures for the nine months period ended December 31, 2023, which was subjected to Limited Review.
4. Figures for the previous periods have been regrouped / reclassified wherever considered necessary.
5. The group operates in a single segment of providing Contract Research and Manufacturing Services.
6. During the Q4 March 2024, the company has increased the partnership interest in Anugraha Chemicals to 50.60%. Consequently, the firm became subsidiary in Q4 and the financials of firm are consolidated with the company.
The company acquired 99.86% of the total outstanding equity shares of Adita Bio Sys Pvt Ltd in Q4. Consequently, the financials of Adita are consolidated with the company.

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**

**Venu Madhava Kaparthy
Director
DIN: 00021699**

Consolidated Balance Sheet

All figures in Rs. Lacs unless otherwise specified

Particulars	As at	As at
	31 March 2024	31 March 2023
ASSETS		
Non-current assets		
Property, plant and equipment	2,834.03	10.61
Capital work-in-progress	700.10	200.00
Right-of-use assets	311.73	-
Other intangible assets	54.51	-
Goodwill on Business purchase	3,141.66	-
Financial assets		
(i) Other financial assets	58.01	8.50
Deferred tax assets (net)	666.79	270.75
Other non-current assets	14.04	137.06
Total non-current assets	7,780.87	626.92
Current assets		
Inventories	359.14	-
Financial assets		
(i) Investments	-	330.52
(ii) Trade receivables	267.87	205.43
(iii) Cash and cash equivalents	480.40	1,275.42
Other current assets	245.79	20.19
Total current assets	1,353.20	1,831.55
TOTAL ASSETS	9,134.07	2,458.47
EQUITY AND LIABILITIES		
Equity		
Equity share capital	3,526.78	2,144.38
Other equity	3,677.91	101.63
Equity attributable to the owners of the Company	7,204.69	2,246.01
Non-controlling Interest	(155.03)	-
Total equity	7,049.67	2,246.01
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	358.54	-
(i) Lease liabilities	246.75	-
(iii) Other financial liabilities	260.00	-
Provisions	61.54	-
Total non-current liabilities	926.83	-
Current liabilities		
Financial liabilities		
(i) Borrowings	176.70	-
(ii) Lease liabilities	71.29	-
(iii) Trade payables		
total outstanding dues of micro and small enterprises	405.41	-
total outstanding dues of creditors other than micro and small enterprises	106.42	188.31
(iv) Other financial liabilities	339.94	16.67
Provisions	7.61	-
Other current liabilities	50.21	7.49
Total Current Liabilities	1,157.58	212.47
TOTAL EQUITY AND LIABILITIES	9,134.07	2,458.47

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Director
DIN: 00021699

Consolidated Statement of Cash Flows

All figures in Rs. Lacs unless otherwise specified

Particulars	Year ended 31 March 2024	Year ended 31 March 2023
Cash flows from operating activities		
Net Profit Before Tax	(1,562.14)	(990.76)
<i>Adjustments to reconcile profit before tax to net cash flows:</i>		
Depreciation	172.49	1.68
Interest income	(21.55)	-
Finance Cost	156.83	-
Liabilities written back	(64.61)	-
(Gain)/ Loss on sale of fixed asset	2.02	3.06
Provision for bad debts	80.81	-
Property Plant and Equipment and other assets written-off	62.29	-
<i>Adjustments for changes in working capital:</i>		
(Increase)/decrease in inventories	71.64	88.76
(Increase)/decrease in trade receivables	235.68	70.06
(Increase)/decrease in other current assets	(252.09)	456.87
Increase/(decrease) in trade payables	(124.02)	(42.27)
Increase/(decrease) in other financial liabilities	534.17	16.67
Increase/(decrease) in other provisions	63.58	-
Increase/(decrease) in other current liabilities	(417.07)	(6.00)
Cash generated from/(used in) operations	(1,061.96)	(401.93)
Income tax paid	-	-
Net cash flows generated from/(used in) operating activities (A)	(1,061.96)	(401.93)
Cash flows from investing activities		
Purchase of property, plant and equipment incl. CWIP	(2,286.25)	(167.29)
Sale of property, plant and equipment	14.65	-
Interest on bank deposits	20.83	-
Purchase of Siri Industries through Slump Sale	(75.02)	-
Payment to shareholders towards acquisition of subsidiary	(5,173.25)	-
Investment in partnership firm	-	(327.04)
Net cash flow generated from/(used in) investing activities (B)	(7,499.04)	(494.33)
Cash flow from Financing activities		
Proceeds from borrowing	153.00	-
Repayment of borrowing	(179.55)	-
Proceeds from issue of equity shares	7,801.16	2,096.25
Proceeds from share application money	-	34.69
Proceeds from Issue of preference share capital	300.00	-
Proceeds from partners' capital in subsidiary	0.10	-
Repayment of partners' capital in subsidiary	(119.04)	-
Interest on loan	(123.67)	-
Repayment of lease liabilities	(66.01)	-
Net cash flow generated from/(used in) financing activities (C)	7,765.98	2,130.94
Net increase in cash and cash equivalents (A+B+C)	(795.02)	1,234.67
Cash and cash equivalents at the beginning of the year	1,275.42	40.74
Cash and cash equivalents at the end of the year	480.40	1,275.42
Cash and cash equivalents comprise		
Balances with banks in current & deposit accounts	171.55	1,275.10
Deposits with original maturity of less than 3 months	306.71	-
Cash on hand	2.15	0.31
Total cash and cash equivalents	480.40	1,275.42

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Director
DIN: 00021699



Pharmaids Pharmaceuticals Limited

Date: 28.05.2024

To,
The Manager
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai – 400001

Dear Sir/Madam,

BSE Scrip: PHARMAID | Code: 524572 ISIN: INE117D01018

Subject: Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligation and Disclosure Requirements), Regulations, 2015

DECLARATION

I, **Venu Madhava Kaparthy**, Whole-time Director of Pharmaids Pharmaceuticals Limited (“Company”) hereby confirm and declare that M/s. PPKG & Co, Chartered Accountants (Firm Registration No. 009655S) Statutory Auditors of the Company, have given the Audit Report with Unmodified Opinion on the Audited Financial Results (Standalone & Consolidated) for the year ended March 31, 2024.

Kindly take the declaration on your records.

Yours’ Faithfully

For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Director
DIN:00021699